Connexion
M'inscrire

Votre recherche

Filtres

Project précédent
Projet suivant
Nous verifions auprès de chaque centre si des nouvelles informations sont disponibles

202303144RINA

Using gut microbial gbu gene testing to estimate host tmao production capacity
Source : Importé depuis le centre

Référence clinicaltrials.gov: NCT05980884
gbu gene cluster
TMAO
gut microbiota
red meat
cardiovascular disease
Source :Importé depuis le centre
TMAO
carnitine
cardiovasculaire
microbiote
gène
bbu
fécal
intestin
bactéries
clinique
recherche
Mots clés générés par intelligence artificielle
Recrutement fermé
Dernière modification : 2026/01/11
Type de recherche

Interventionnel


Population cible

Condition médicale (spécialité visée)

Donnée non disponible

Profil des participants

Limites d'âge
minimum : 18 ans maximum : 70 ans
Sexe(s) des participants

ALL

Source : Importé depuis le centre

Critères de sélection

Critères d'inclusion

Inclusion Criteria:

* Adult with age between 18 to 70
* Must be able to swallow tablets

Exclusion Criteria:

* Antibiotics use within one month
* L-carnitine supplement use within one month
* Chronic diarrhea
* Myasthenia gravis
* Diabetes mellitus
* Parathyroid disorders
* Chronic kidney disease
* Epilepsy
* Severe anemia
* Cardiovascular diseases.

Source : Importé depuis le centre

Thérapie ou Intervention proposée

Cohortes
Nom Condition médicale Traitement État du recrutement
L-Carnitine supplementation Participants are required to take a capsule containing 500mg L-carnitine/day continuous for 7-10 days. During the intervention, participants are asked to collect urine sample and dietary record each day. Blood and fecal samples will be collected before and after the intervention. Each participant needs to complete a food frequency questionnaire. Donnée non disponible
  • Inconnu
  • L-Carnitine supplementation
    État du recrutement
    unknown
    Données à jour depuis : 11 janvier 2026

    Description de l'étude

    Résumé de l'étude

    The risk of cardiovascular diseases from red meat consumption varies among individuals due to variations in gut microbiota. L-carnitine in red meat can be converted to TMAO in the body by certain bacteria. Not everyone experiences a significant increase in TMAO levels after consuming carnitine. Gut microbiota differences are observed between high and low TMAO producers. The presence of the gbu gene in gut microbiota is linked to TMAO production. This clinical research aims to determine if the gbu gene can predict TMAO levels after dietary carnitine intake.

    Source : Importé depuis le centre

    The risk of developing cardiovascular diseases due to the consumption of red meat varies among individuals, and this may be attributed to differences in the composition and function of gut microbiota. Studies have found that red meat, rich in L-carnitine, may be metabolized by certain anaerobic bacteria in the intestines to produce trimethylamine N-oxide (TMAO) in the human body. Previous research utilizing the oral carnitine challenge test (OCCT) revealed that not everyone experiences a significant increase in blood TMAO levels after consuming carnitine. Moreover, individuals with high TMAO production and low TMAO production showed distinct differences in their gut microbiota.

    Furthermore, we have discovered a significant correlation between the abundance of the gbu gene in gut microbiota and the production of TMAO in response to dietary carnitine intake. Therefore, through the design of clinical research, we aim to investigate and assess whether the abundance of the gbu gene in gut microbiota can predict the levels of TMAO produced in the human body under dietary carnitine intake.

    Source : Importé depuis le centre

    Sites

    Centres participants

      1 centres
    • NATIONAL TAIWAN UNIVERSITY HOSPITAL

      Taipei

      OTHER, TAIWAN

      Recrutement local
      État du recrutement: FERMÉ

    Dernière modification : 11 janvier 2026
    Données à jour depuis : 13 jan.
    Origine des données : clinicaltrials.gov
    Référence clinicaltrials.gov: NCT05980884